Skip to content

Exagen Inc. XGN Contract Liabilities

Contract Liabilities at other companies

Idexx Laboratories logo
Idexx LaboratoriesIDXX
$32.31M+20.5%
Janux Therapeutics logo
Janux TherapeuticsJANX
$8.68M
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$12.65M+644%
Agilent Technologies logo
Agilent TechnologiesA

Other financials

Income statement

See full
Revenue$17.3M+11.7%
Gross profit$10.2M+11.9%
Operating income-$3.4M-1.5%
Net income-$4.0M-5.7%
EPS (diluted)-$0.17+15.0%

Balance sheet

See full
Cash & equivalents$21.7M+90.6%
Total debt$27.1M+15.8%
Total equity$14.4M+125%
Total assets$52.0M+28.9%

Cash flow

See full
Operating cash flow-$10.4M+2.4%
CapEx$228.0K+102%
Free cash flow-$10.6M+1.3%

Valuation

See full
Market cap$112.34M-26.5%
Enterprise value$117.78M-20.3%
P/S1.6×-1.0×

Profitability

See full
Gross margin58.3%-1.0pp
Operating margin-20.6%-2.9pp
Net margin-29.5%+2.5pp
FCF margin-27.5%

Returns & leverage

See full
Return on equity-193.6%+355pp
Debt / equity1.9×-1.8×
Current ratio3.5×+1.1×

Where this comes from

Reported directly by Exagen Inc. in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiability.

The official record: Exagen Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exagen Inc.'s contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exagen Inc.'s contract liabilities?
Exagen Inc. (XGN) reported contract liabilities of $700K in Q1 2026.
How has Exagen Inc.'s contract liabilities changed year-over-year?
Exagen Inc.'s contract liabilities decreased by 22.2% year-over-year, from $900K to $700K.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.